Compare · BLLN vs LH
BLLN vs LH
Side-by-side comparison of BillionToOne Inc. (BLLN) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLLN and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH carries a market cap of $25.85B.
- Over the past year, BLLN is down 22.5% and LH is up 14.6% - LH leads by 37.1 points.
- LH has been more active in the news (7 items in the past 4 weeks vs 3 for BLLN).
- LH has more recent analyst coverage (25 ratings vs 8 for BLLN).
- Company
- BillionToOne Inc.
- Labcorp Holdings Inc.
- Price
- -
- -
- Market cap
- -
- $25.85B
- 1M return
- +10.49%
- -0.86%
- 1Y return
- -22.47%
- +14.64%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 3
- 7
- Recent ratings
- 8
- 25
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest BLLN
- SEC Form DEFA14A filed by BillionToOne Inc.
- SEC Form DEF 14A filed by BillionToOne Inc.
- BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026
- BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
- SEC Form 10-K filed by BillionToOne Inc.
- BillionToOne Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance
- SEC Form SCHEDULE 13G filed by BillionToOne Inc.
- BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
- SEC Form SCHEDULE 13G filed by BillionToOne Inc.
Latest LH
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
- Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
- Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
- SEC Form DEFA14A filed by Labcorp Holdings Inc.
- SEC Form DEF 14A filed by Labcorp Holdings Inc.
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Declares Quarterly Dividend
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Announce First Quarter Financial Results on April 30, 2026
- SEC Form 4 filed by Schechter Adam H